Japan Market Entry Services for Drug Development

Work with CMIC’s Experts for Optimized Success for Japan Market Entry

0
Offices in Japan
0
CDMO plants in Japan
0
Laboratories in Japan
0rd
Largest pharmaceutical market worldwide

Japan Market Entry

Streamline Your Japan Market Entry Strategy with CMIC Group

CMIC Group delivers integrated Japan market entry services for drug development, helping global pharmaceutical and biotech companies navigate clinical development, regulatory strategy, and commercialization. With 36 offices, 4 CDMO plants, and 7 laboratories in Japan alone, we provide the local infrastructure and expertise needed to support a successful entry.

CMIC Japan market entry experts

Why CMIC

Benefits of Choosing CMIC Group as a Japan Market Entry Partner for Pharmaceuticals

CMIC Group brings the integrated expertise pharmaceutical sponsors need to enter and grow in Japan, connecting market strategy, clinical development, regulatory representation, manufacturing, and commercialization support for a more efficient route to market.

Multiphase strategy and feasibility

Access market analysis, competitive assessments, and Target Product Profile (TPP) development to evaluate opportunity and guide go/no-go decisions.

Flexible support at every stage

Receive guidance from preclinical development and clinical trials through post-approval activities and commercialization.

In-country clinical representation

CMIC Group can serve as your authorized In-Country Clinical Caretaker (ICCC) and support PMDA regulatory discussions.

MAH, pricing, and orphan drug pathways

Benefit from MAH/dMAH services, NHI pricing support, and specialized orphan drug launch options.

Integrated end-to-end infrastructure

Connect clinical CRO, site network, CDMO manufacturing, pharmacovigilance, and localized medical affairs services through one partner.

Ready to navigate the Japanese market with confidence?

Market Opportunity

Values and Potential of the Japanese Pharmaceutical Market

Japan is the world’s third-largest pharmaceutical market, offering prime drug development opportunities alongside a strong acceptance of new modalities and trusted investigator-patient relationships. Companies can take advantage of these benefits by working with an experienced provider of Japan market entry services for drug development.

Universal Health Insurance

Japan’s unique system grants every citizen equal access to high-quality medical care with minimal personal costs.

New Drug Pricing

NHI listings occur four times annually (Feb, May, Aug, and Nov), adding approved drugs within sixty to ninety days of marketing approval.

Regulatory Advantages

Navigating the Regulatory Landscape in Japan and Its Advantages

Rapid Approval

  • Faster approval time than FDA: Approvals are, in many cases, faster than at other regulatory authorities. A recent study showed that the PMDA had the shortest median approval time and the smallest interquartile range for approving new active substances between 2013 and 2022, ahead of the U.S. FDA.
  • Comparable approval time with FDA in both expedited and standard reviews, with the smallest difference between review types.
New active substance (NAS) median approval time for six regulatory authorities in 2013-2022

Rapid Approval Evidence: “New active substance (NAS) median approval time for six regulatory authorities in 2013-2022”

Regulatory Systems in Japan

Discussions with PMDA will become smoother by incorporating Japan into global trials. CMIC’s Japan market entry services for drug development help sponsors include Japan in their global regulatory strategy early.

High Quality Data

Consistent and high-quality clinical data derived from scientific knowledge and highly compliant characteristics of investigators and patients.

Step-by-Step Guidance

Step-by-Step Guidance for Japan Market Entry and Early Drug Development Strategies

Strategic Options for Japan Market Entry

CMIC’s comprehensive support, including the option of Marketing Authorization Holder (MAH), is a unique service that no other company can offer. Our Japan market entry services for drug development offers flexible options for clinical development, regulatory filings, and commercialization.

Option A

License out to other pharma

License Japan business rights to a Japanese company to serve as MAH and submit JNDA, negotiate drug price, distribute and sell product under a license agreement.

Option B

Assign a Marketing Authorization Holder (MAH)

Appoint a Japanese pharmaceutical company to submit the NDA, support drug-pricing negotiations, and manage MAH responsibilities, including sales, distribution, and pharmacovigilance.

Our Approach

How CMIC Group Helps Pharmaceutical Companies Strategize Japan Market Entry

CMIC Group provides specialized Japan market entry services for drug development to overseas pharmaceutical and biotech companies at every stage of development.

From market and competitive analysis, market research, and Target Product Profile (TPP) development to public-funding grant applications and licensing-out strategies, we help assess opportunities, prepare for market entry, and maximize long-term business value.

01

Pre-Entry Strategy

We conduct market feasibility analysis and build target product profiles to guide early-stage go/no-go business decisions. (Proof: Market Entry Strategy)

02

Regulatory & Clinical Execution

Our team coordinates PMDA consultations and clinical trial operations, serving as your legal representative via In-Country Clinical Caretaker (ICCC) services.

03

MAH Partnering & Licensing

We provide unique Marketing Authorization Holder (MAH/dMAH) services, including orphan drug launch pathways via Orphan Pacific Inc., and manage local NHI pricing.

04

Downstream Infrastructure

We integrate clinical site networks, CDMO drug manufacturing, and post-marketing surveillance to support compliant therapeutic distribution.

Connect with our expert consulting team to strategize your entry into the Japanese market today.

Pre-Entry Decision-Making

Six Key Elements Supporting Pre‑Entry Decision‑Making

Six Key Elements Supporting Pre‑Entry Decision‑Making

Market Analysis

Assess the Japanese market, competitive landscape, and entry barriers to identify opportunities. Our Japan market entry services support informed decisions from the outset.

Business Feasibility Assessment

Evaluate in-licensing opportunities, key risks, success conditions, and decision points.

Business Strategy Development

Develop grant application, investor, market entry, expansion, and licensing-out strategies aligned with business goals.

Development Strategy

Build a Japan-focused development roadmap with clear priorities, stages, and regulatory considerations.

TPP Development Support

Create a Target Product Profile to align development, business, and partnering decisions.

Partnering Strategy

Identify suitable local partners and define the right partnership model, timing, and discussion priorities for your Japan market entry services.

End-to-End Solutions

CMIC’s End-to-End Solutions to Support Japan Market Entry

Full List of Services CMIC Provides

  • Clinical Operations
  • Clinical Site Network Services / Med Concierge Service
  • Pharmacovigilance
  • Sales & Marketing
  • Medical Affairs
  • Medical Device Development

  • Orphan Drug Development

Orphan Drugs

Get to know OrphanPacific, Inc.

OrphanPacific, Inc. is a pharmaceutical company within CMIC Group with manufacturing and marketing authorization licenses and can serve as the MAH for your orphan drugs in Japan.

Keiko Oishi, President, CMIC Group

Podcast

Executive Insights on Accelerating Drug Development and Market Access in Japan & Asia-Pacific

Featuring Keiko Oishi, President, CMIC Group

Keiko Oishi discusses how evolving policies and regulatory flexibility are shaping drug development and market access across Japan and Asia-Pacific.

  • Japan’s evolving regulatory environment
  • Japan and South Korea as extensions of Western development programs
  • Benefits of an integrated service model
  • Key cultural, regulatory and operational considerations
  • Long-term APAC opportunities and challenges

Industry Perspective

PMDA Opens the Door to Innovative Products in Japan

Learn what the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan has to say about the unique benefits of the Japan Pharmaceutical Market and the countless opportunities to sponsors developing innovative therapeutic products in Japan. Read the full article on DIA’s website by clicking the button below.

FAQ

FAQ’s About Japan Market Entry Services

Navigate regulatory pathways and optimize your commercial launch with these key insights on Japan market entry services for drug development.

Which APAC country is best for pharmaceutical drug development and market entry?

Japan is a strategic hub for pharmaceutical drug development and market entry in Asia-Pacific. As the world’s third-largest pharmaceutical market, it combines a well-established healthcare ecosystem with efficient PMDA regulatory reviews. Across emerging APAC markets, clinical trial expenditures for procedures, diagnostic tests, and site visits average 30% to 40% lower than in North America and Europe, helping sponsors reduce development costs while expanding their regional programs. (Source: Clinical Leader)

CMIC Group is the leading firm specializing in pharmaceutical market entry in Japan for drug development. Our company provides specialized Japan market entry services for drug development in Tokyo, acting as an In-Country Clinical Caretaker to streamline PMDA consultations and manage local operations.

You can find market entry services for pharmaceutical drug development in Japan through CMIC Group’s Tokyo headquarters. We deliver comprehensive Japan market-entry services for drug development, assisting global sponsors with strategic consulting, local clinical trials, CDMO manufacturing, and navigation of local health insurance pricing.